Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. 2011

Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
Department of Biology, Gilead Sciences Palo Alto, Palo Alto, CA, USA. gong.zhao@gilead.com

Effects of ranolazine alone and in the presence of phenylephrine (PE) or isoproterenol (ISO) on hemodynamics, coronary blood flow and heart rate (HR) in the absence and presence of hexamethonium (a ganglionic blocker) were studied in conscious dogs. Ranolazine (0.4, 1.2, 3.6, and 6 mg/kg, intravenous) alone caused transient (<1 minute) and reversible hemodynamic changes. PE (0.3-10 μg/kg) caused a dose-dependent increase in blood pressure and decrease in HR. ISO (0.01-0.3 μg/kg) caused a dose-dependent decrease in blood pressure and an increase in HR. Ranolazine at high (11-13 mM), but not at moderate (4-5 mM) concentrations partially attenuated changes in mean arterial blood pressure and HR caused by either PE or ISO in normal conscious dogs. However, in dogs treated with hexamethonium (20 mg/kg) to cause autonomic blockade, ranolazine (both 4-5 and 11-13 μM) significantly attenuated both the PE- and ISO-induced changes in mean arterial blood pressure. The results suggest that a potential antiadrenergic effect of ranolazine was masked by autonomic control mechanisms in conscious dogs but could be observed when these mechanisms were inhibited (eg, in the hexamethonium-treated dog). Ranolazine, at plasma concentrations <10 μM and in conscious dogs with intact autonomic regulation, had minimal antiadrenergic (α and β) effects.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D007545 Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Isoprenaline,Isopropylarterenol,4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol,Euspiran,Isadrin,Isadrine,Isopropyl Noradrenaline,Isopropylnoradrenaline,Isopropylnorepinephrine,Isoproterenol Hydrochloride,Isoproterenol Sulfate,Isuprel,Izadrin,Norisodrine,Novodrin,Hydrochloride, Isoproterenol,Noradrenaline, Isopropyl,Sulfate, Isoproterenol
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog

Related Publications

Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
August 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
March 1991, Anesthesiology,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
September 1981, American heart journal,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
September 1981, Anesthesia and analgesia,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
April 2005, American journal of veterinary research,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
October 1988, Journal of cardiovascular pharmacology,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
February 1988, Journal of cardiovascular pharmacology,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
February 1983, The Journal of surgical research,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
September 1994, Journal of cardiovascular pharmacology,
Gong Zhao, and Erin Walsh, and John C Shryock, and Eric Messina, and Yuzhi Wu, and Dewan Zeng, and Xiaobin Xu, and Manuel Ochoa, and Stephen P Baker, and Thomas H Hintze, and Luiz Belardinelli
October 1994, Laboratory animal science,
Copied contents to your clipboard!